R&D

Zai Lab licenses other companies’ drugs for commercialization in China.

FAST NEWS: Zai Lab’s loss narrows on improved drug sales

The Latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 33.7% to $80.3 million in the second quarter of this year. Looking Up: The company's net product revenue for…
9688.HK ZLAB.US
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks.

China-focused Tigermed staves off biopharma gloom

Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
3347.HK 300347.SHE
Biotech company Zai Lab reported Wednesday that its loss narrowed 24.5% to $335 million last year.

FAST NEWS: Zai Lab’s loss narrows on strengthening sales

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
9688.HK ZLAB.US
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.

Junshi hopes new scientist CEO can cure its woes

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
1877.HK 688180.SHG
Biotech company Zai Lab announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier.

FAST NEWS: Zai Lab’s loss narrows on growing revenue

The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) announced Wednesday that its loss narrowed 57% to $69.15 million in the third quarter from $161 million a year earlier. Looking up: The…
ZLAB.US 9688.HK

FAST NEWS: U.S. investment firm boosts WuXi AppTec stake

The latest: The Capital Group, a U.S. asset manager, disclosed it purchase 2.52 million Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) for HK$177 million ($20.8 million), raising…
2359.HK 603259.SHG

Recent Articles

RELATED ARTICLES

  1. Biotech company Zai Lab reported Wednesday that its loss narrowed 24.5% to $335 million last year.
    FAST NEWS: Zai Lab’s loss narrows on strengthening sales
    9688.HK ZLAB.US
  2. FAST NEWS: Zai Lab’s loss narrows on growing revenue
    ZLAB.US 9688.HK
  3. CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  4. Everest reaches new heights on growing drug sales
    1952.HK
  5. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  6. BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva